The IRIS trial: A clinical trial for people living with active lupus nephritis (LN)

Brief description of study

IRIS is looking to see if a new FDA-approved therapy called SAPHNELO® may be effective in treating people with active LN. SAPHNELO® is the brand name for the medication anifrolumab. This medication is a monoclonal antibody. It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-a and interferon-B.

Clinical Study Identifier: s23-00957

ClinicalTrials.gov Identifier: NCT05138133

Principal Investigator: Amit Saxena.

Other Investigators: Howard Belmont, Janine M. Sullivan, Abhimanyu Amarnani.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies